Association of run-in periods with weight loss in obesity randomized controlled trials

Obesity Reviews

Volumn 15, Issue 1, 2014, Pages 68-73

  Affuso, O ^a   Kaiser, K A ^a   Carson, T L ^a,b   Ingram, K H ^c   Schwiers, M ^d   Robertson, H ^e   Abbas, F ^f   Allison, D B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c KENNESAW STATE UNIVERSITY   (United States)

^d ETHICON INC   (United States)

^e Seton Healthcare Family   (United States)

^f Maricopa Integrated Health System   (United States)

Author keywords

Obesity; Randomized clinical trials; Run in periods

Indexed keywords

ARTICLE; BODY MASS; HUMAN; META ANALYSIS; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION;

OBESITY; RANDOMIZED CLINICAL TRIALS; RUN-IN PERIODS;

ADULT; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEX DISTRIBUTION; WEIGHT GAIN; WEIGHT LOSS;

EID: 84890437250     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12111     Document Type: Article

References (16)

1. NIDDK. Obesity Clinical Research. 2004. [WWW document]. URL http://www.niddk.nih.gov/patient/patientobesity.htm (accessed 20 May 2013).
2. Berger VW, Rezvani A, Makarewicz VA. Direct effect on validity of response run-in selection in clinical trials. Control Clin Trials 2003; 24: 156-166.
3. Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obes Rev 2003; 4: 25-42.
4. Pablos-Mendez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 1998; 279: 222-225.
5. Wirth A, Krause H. Long-term weight loss with sibutramine. JAMA 2001; 286: 1331-1339.
6. FDA. Guidance for the clinical evaluation of weight-control drugs. Fed Regist February 27, 1997 (62 FR 8961). 1996. [WWW document]. URL http://www.fda.gov/ohrms/dockets/98fr/03d-0570-gdl0001.pdf (accessed 20 May 2013).
7. Sjöström L, Astrup A, Richelse B etal. Debate Speech: run in periods are not appropriate in most drug trials of obesity. Int J Obes 2000; 24(1 Suppl.): S12.
8. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Endocrinologic and metabolic drugs. Advisory subcommittee [transcript]. September 8, 2004; Bethesda, MD. Quote from Dr S Yanovski. [WWW document]. URL http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4068T1.htm (accessed 20 May 2013).
9. Orloff DG. FDA 2004: Toward new therapeutics for obesity. Presentation before the Science Board to the Food and Drug Administration, 22 April 2004. [WWW document] URL http://www.fda.gov/ohrms/dockets/ac/04/slides/4039s1.htm.
10. European Medicines Agency. Committee For Medicinal Products For Human Use (CMPH). Guideline on clinical investigation of medicinal products used in weight control (draft). 2006. [WWW document] URL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003213.pdf (accessed 20 May 2013).
11. Pi-Sunyer F, Aronne LJ, Heshmati HM etal. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
12. FDA. Guidance for industry developing products for weight management (draft). Fed Regist 1 February 2007 (Revision 1). 2007. [WWW document] URL http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071612.pdf (accessed 20 May 2013).
13. Fabricatore AN, Wadden TA, Moore RH etal. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009; 10: 333-341.
14. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Concept paper on the need for revision of the guideline of medical products used in weight control (draft). 2012. [WWW document] URL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133166.pdf (accessed 20 May 2013).
15. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Ann Intern Med 2010; 152: 726-732.
16. West DS, Harvey-Berino J, Krukowski RA, Skelly J. Pretreatment weight change is associated with obesity treatment outcomes. Obesity (Silver Spring) 2011; 19: 1791-1795.